首页> 外文期刊>Internal medicine. >Successful Treatment of Persistent MRSA Bacteremia using High-dose Daptomycin Combined with Rifampicin
【24h】

Successful Treatment of Persistent MRSA Bacteremia using High-dose Daptomycin Combined with Rifampicin

机译:大剂量达托霉素联合利福平成功治疗持久性MRSA细菌

获取原文
获取原文并翻译 | 示例
       

摘要

We herein report a case of persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia that was successfully treated with combination therapy consisting of high-dose daptomycin (DAP, 10 mg/kg) and rifampicin. The patient's condition was complicated with multiple infectious foci, including an iliopsoas abscess and epidural abscess, as well as discitis and spondylitis at the cervical, thoracic and lumbar levels. Monotherapy treatments with vancomycin, linezolid and usual-dose DAP were all ineffective. It has been shown that usual-dose DAP administration may result in the emergence of a resistant strain and treatment failure. We would like to emphasize the importance of high-dose DAP therapy for MRSA bacteremia, a condition with a potentially high mortality rate.
机译:我们在此报告了一种持续的耐甲氧西林金黄色葡萄球菌(MRSA)菌血症的病例,该病例已成功地由高剂量达托霉素(DAP,10 mg / kg)和利福平组成的联合疗法治疗。患者的病情很复杂,并伴有多个感染灶,包括肌脓肿和硬膜外脓肿,以及颈,胸和腰椎间盘炎和脊柱炎。万古霉素,利奈唑胺和常规剂量DAP的单药治疗均无效。已经显示,常规剂量的DAP给药可能导致耐药菌株的出现和治疗失败。我们想强调大剂量DAP治疗对于MRSA菌血症的重要性,MRSA菌血症具有潜在的高死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号